Study on Belantamab Mafodotin and Feladilimab for Treating Relapsed or Refractory Multiple Myeloma

Inclusion Criteria

• Must be 18 years or older.
• Must have a confirmed diagnosis of multiple myeloma.
• Must have received at least three previous treatments for multiple myeloma, including specific types of drugs.
• If you had a stem cell transplant, it must have been more than 100 days ago, and you should not have any active infections.
• Must be in good general health, with a performance status score of 0 or 1, unless bone issues from multiple myeloma are the only reason for a score of 2.
• Must have measurable disease, which means certain levels of proteins in the blood or urine.
• If you have tested positive for Hepatitis B, you can still participate if certain conditions are met.
• Can be taking low doses of steroids or using inhaled or eye-drop steroids.

Exclusion Criteria

• Have current eye problems, except for mild issues.
• Have heart-related health risks.
• Have allergies to the study drugs or similar medications.
• Have an active infection needing treatment.
• Have used other monoclonal antibodies or anti-myeloma treatments recently.
• Have had radiation therapy recently.
• Have had a donor stem cell transplant.
• Have had CAR-T cell therapy with chemotherapy recently.
• Have had major surgery recently.
• Have used experimental treatments recently.
• Have severe side effects from previous treatments.
• Have had a blood transfusion recently.
• Should not receive live vaccines recently or during the study.
• Have active kidney problems, except for protein in urine from multiple myeloma.
• Have HIV, unless certain conditions are met.
• Have autoimmune diseases needing treatment in the past two years.
• Have had heart inflammation recently.